US equities
|
MU
$924.18
▼-3.04%
NVDA
$220.44
▼-3.54%
AAPL
$342.87
▲+0.47%
AMD
$572.14
▼-5.51%
META
$736.11
▼-3.46%
TSLA
$363.98
▼-3.00%
SPCX
$151.72
▼-3.08%
SNDK
$1,411.97
▼-4.75%
MU
$924.18
▼-3.04%
NVDA
$220.44
▼-3.54%
AAPL
$342.87
▲+0.47%
AMD
$572.14
▼-5.51%
META
$736.11
▼-3.46%
TSLA
$363.98
▼-3.00%
SPCX
$151.72
▼-3.08%
SNDK
$1,411.97
▼-4.75%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Rhythm Pharmaceuticals, Inc. - Common Stock
(NQ:
RYTM
)
87.86
+1.25 (+1.44%)
Delayed Quote
Updated: 2:31 PM EDT, Oct 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Rhythm Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
October 13, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
September 22, 2026
-- First targeted therapy approved in Canada for patients four years and older living with acquired hypothalamic obesity (HO) --
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting
September 10, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
August 24, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
August 17, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or
August 11, 2026
-- MHRA grants authorization for patients 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment --
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
August 04, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
August 04, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
August 04, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
July 21, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
July 08, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
June 15, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
June 13, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
June 12, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
May 29, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
May 28, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
May 26, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
May 12, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
May 06, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
May 05, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
May 04, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
May 01, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
April 09, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Changes to Board of Directors
April 03, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
March 26, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
March 19, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
March 16, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
March 01, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
February 26, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
February 17, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
